BidaskClub upgraded shares of ANI Pharmaceuticals (NASDAQ:ANIP) from a hold rating to a buy rating in a report issued on Friday, October 19th.
A number of other research analysts have also issued reports on the stock. Cantor Fitzgerald set a $74.00 price objective on shares of ANI Pharmaceuticals and gave the company a buy rating in a report on Wednesday, October 3rd. ValuEngine upgraded shares of ANI Pharmaceuticals from a sell rating to a hold rating in a report on Friday, September 28th. Canaccord Genuity set a $75.00 price target on shares of ANI Pharmaceuticals and gave the stock a buy rating in a report on Thursday, August 16th. Finally, Zacks Investment Research lowered ANI Pharmaceuticals from a buy rating to a hold rating in a research note on Tuesday, July 10th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The stock has a consensus rating of Hold and an average target price of $71.00.
Shares of ANIP traded down $1.38 during mid-day trading on Friday, reaching $52.66. The company had a trading volume of 78,559 shares, compared to its average volume of 73,741. The company has a market cap of $653.68 million, a P/E ratio of 14.59 and a beta of 2.64. ANI Pharmaceuticals has a 1-year low of $48.40 and a 1-year high of $74.70. The company has a current ratio of 3.34, a quick ratio of 2.89 and a debt-to-equity ratio of 1.04.
ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings data on Tuesday, November 6th. The specialty pharmaceutical company reported $1.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.17 by $0.12. The business had revenue of $50.70 million during the quarter, compared to analyst estimates of $50.97 million. ANI Pharmaceuticals had a net margin of 0.23% and a return on equity of 28.39%. The firm’s quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter last year, the business earned $1.11 EPS. On average, equities analysts forecast that ANI Pharmaceuticals will post 4.49 EPS for the current year.
Large investors have recently added to or reduced their stakes in the company. Aperio Group LLC boosted its stake in shares of ANI Pharmaceuticals by 21.3% during the second quarter. Aperio Group LLC now owns 5,799 shares of the specialty pharmaceutical company’s stock valued at $387,000 after purchasing an additional 1,019 shares during the period. Strs Ohio raised its holdings in shares of ANI Pharmaceuticals by 17.3% during the second quarter. Strs Ohio now owns 12,200 shares of the specialty pharmaceutical company’s stock valued at $814,000 after acquiring an additional 1,800 shares in the last quarter. First Manhattan Co. raised its holdings in shares of ANI Pharmaceuticals by 48.0% during the third quarter. First Manhattan Co. now owns 215,695 shares of the specialty pharmaceutical company’s stock valued at $12,195,000 after acquiring an additional 70,000 shares in the last quarter. Cadence Capital Management LLC raised its holdings in shares of ANI Pharmaceuticals by 83.3% during the second quarter. Cadence Capital Management LLC now owns 46,108 shares of the specialty pharmaceutical company’s stock valued at $3,080,000 after acquiring an additional 20,947 shares in the last quarter. Finally, Phocas Financial Corp. bought a new position in shares of ANI Pharmaceuticals during the second quarter valued at approximately $2,788,000. 61.10% of the stock is owned by hedge funds and other institutional investors.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and hydrocortisone enema and cortenema to treat ulcerative colitis.
Featured Article: What does cost of debt say about a company’s financial health?
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.